- Home
- VIR vs VRDN Comparison
VIR vs VRDN Comparison
Compare VIR & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIR
- VRDN
- Stock Information
- Founded
- VIR 2016
- VRDN 2006
- Country
- VIR United States
- VRDN United States
- Employees
- VIR N/A
- VRDN N/A
- Industry
- VIR Biotechnology: Pharmaceutical Preparations
- VRDN Medical Specialities
- Sector
- VIR Health Care
- VRDN Health Care
- Exchange
- VIR Nasdaq
- VRDN Nasdaq
- Market Cap
- VIR 844.9M
- VRDN 1.0B
- IPO Year
- VIR 2019
- VRDN N/A
- Fundamental
- Price
- VIR $5.07
- VRDN $13.97
- Analyst Decision
- VIR Strong Buy
- VRDN Strong Buy
- Analyst Count
- VIR 7
- VRDN 12
- Target Price
- VIR $32.86
- VRDN $38.50
- AVG Volume (30 Days)
- VIR 1.6M
- VRDN 785.8K
- Earning Date
- VIR 05-07-2025
- VRDN 05-06-2025
- Dividend Yield
- VIR N/A
- VRDN N/A
- EPS Growth
- VIR N/A
- VRDN N/A
- EPS
- VIR N/A
- VRDN N/A
- Revenue
- VIR $20,861,000.00
- VRDN $302,000.00
- Revenue This Year
- VIR N/A
- VRDN N/A
- Revenue Next Year
- VIR $15.32
- VRDN $21,976.14
- P/E Ratio
- VIR N/A
- VRDN N/A
- Revenue Growth
- VIR N/A
- VRDN 4.86
- 52 Week Low
- VIR $4.32
- VRDN $9.90
- 52 Week High
- VIR $14.45
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- VIR 47.79
- VRDN 56.41
- Support Level
- VIR $4.72
- VRDN $13.37
- Resistance Level
- VIR $5.24
- VRDN $14.18
- Average True Range (ATR)
- VIR 0.32
- VRDN 0.68
- MACD
- VIR 0.09
- VRDN 0.13
- Stochastic Oscillator
- VIR 70.09
- VRDN 75.40
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).